rs28399664
▶GWAS Catalog Trait Associations (15)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (15)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
Alzheimer disease, family history of Alzheimer’s disease
Willett JDS et al. “Identification of 16 novel Alzheimer's disease loci using multi-ancestry meta-analyses.” Alzheimer's & Dementia : the Journal of the Alzheimer's Association 21(2):e14592 (2025)
Allele G
OR —
p 3.0e-42
N 404,467
Large GWAS
multi-ancestry
cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.18
p 2.0e-29
N 115,082
Large GWAS
European
low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.16
p 5.0e-23
N 115,082
Large GWAS
European
low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.15
p 1.0e-21
N 115,082
Large GWAS
European
Alzheimer disease
Lo MT et al. “Identification of genetic heterogeneity of Alzheimer's disease across age.” Neurobiology of Aging 84:243.e1-243.e9 (2019)
Allele G
OR 2.59
p 6.0e-16
N 14,895
Large GWAS
European
Wang H et al. “Similar Genetic Architecture of Alzheimer's Disease and Differential APOE Effect Between Sexes.” Frontiers in Aging Neuroscience 13:674318 (2021)
Allele G
OR 2.57
p 3.0e-9
N 8,682
Large GWAS
European
free cholesterol:total lipids ratio, blood VLDL cholesterol amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.12
p 4.0e-15
N 115,082
Large GWAS
European
triglycerides:total lipids ratio, blood VLDL cholesterol amount
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.12
p 5.0e-15
N 114,160
Large GWAS
European
triglyceride measurement, high density lipoprotein cholesterol measurement
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.12
p 1.0e-14
N 115,082
Large GWAS
European
lipid measurement, high density lipoprotein cholesterol measurement
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.11
p 2.0e-13
N 115,082
Large GWAS
European
high density lipoprotein cholesterol measurement
Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)
Allele C
OR 0.10
p 6.0e-11
N 115,082
Large GWAS
European
This variant is in our database but has no known associations or PRS memberships yet.
Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…